KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Other Operating Expenses (2016 - 2026)

Pacira BioSciences has reported Other Operating Expenses over the past 17 years, most recently at $2.3 million for Q1 2026.

  • For Q1 2026, Other Operating Expenses rose 136.8% year-over-year to $2.3 million; the TTM value through Mar 2026 reached $160.7 million, down 50.26%, while the annual FY2025 figure was $207.0 million, 47.04% down from the prior year.
  • Other Operating Expenses for Q1 2026 was $2.3 million at Pacira BioSciences, down from $54.6 million in the prior quarter.
  • Over five years, Other Operating Expenses peaked at $216.4 million in Q3 2024 and troughed at -$6.2 million in Q1 2025.
  • A 5-year average of $61.4 million and a median of $55.2 million in 2025 define the central range for Other Operating Expenses.
  • Biggest five-year swings in Other Operating Expenses: soared 278.19% in 2024 and later plummeted 110.02% in 2025.
  • Year by year, Other Operating Expenses stood at $89.5 million in 2022, then dropped by 28.17% to $64.3 million in 2023, then dropped by 15.65% to $54.2 million in 2024, then increased by 0.76% to $54.6 million in 2025, then crashed by 95.83% to $2.3 million in 2026.
  • Business Quant data shows Other Operating Expenses for PCRX at $2.3 million in Q1 2026, $54.6 million in Q4 2025, and $48.6 million in Q3 2025.